Business Description
Verrica Pharmaceuticals is a US-based company focused on developing and selling treatments for skin conditions. Its main product, YCANTH, is an approved therapy for molluscum and common warts, while its pipeline includes VP-315, an injectable cancer treatment currently in Phase II trials for basal cell carcinoma and other skin-related cancers. The company works with Torii Pharmaceutical in Japan and licenses technology from Lytix Biopharma to support its growth in both infectious and oncological skin care markets.
